Funding profile · Cancer diagnostics

Digistain

A Delaware parent, a British operating subsidiary, about 1 million dollars of reported equity, 359,812 pounds of Innovate UK money, and no securities filing anywhere. The capital picture has to be assembled from three registries.

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

What the filings show

Reading the filings

1. There is no Form D.Digistain Inc. is a Delaware corporation that took money from Y Combinator and a European fund. An issuer relying on Rule 506 must file a Form D within 15 days of first sale. Nothing exists, which usually means the raise was done under Section 4(a)(2) instead. Either way there is no filed number to check the 1 million dollar figure against.
2. The equity record is trade press.Two outlets carried the August 2022 raise in the same week in the same language: close to a 1 million dollar round, Sofia Angels Ventures alongside Y Combinator, other private VCs and angels. A deal database lists a 1.00 million round and 1.12 million total. No valuation and no share count appear anywhere.
3. The European Investment connection is one step removed.The company profile says it is supported by entities including the European Investment Bank. The record shows the European Investment Fund backed Sofia Angels Ventures, a 13 million euro co-investment fund, which then invested in Digistain as its fourth portfolio company.
4. Non-dilutive money is a third of the visible total.Innovate UK put 349,912 pounds into a companion diagnostic project from January 2023 to June 2024 and 9,900 pounds into a calibration and validation study late in 2024. Both grants are closed and together they are a little under half the reported equity.
5. The UK entity is a small company by its own accounts.Digistain Limited filed dormant accounts for 2020, micro entity accounts for 2021 and total exemption full accounts every year since. Those exemptions mean no published profit and loss account, so there is no public revenue figure for either entity.
6. The 2022 raise was earmarked for an approval that has not arrived.The fund said the money would help the company receive FDA approval, complete new clinical trials, build the team and start commercial activities. Four years on there is no FDA 510(k) or PMA record and no registered trial.
7. The board contracted rather than expanded.A financing round usually adds an investor director. Instead the co-founder left the UK board and gave up his controlling interest on January 27, 2023, the same day a second director was appointed and resigned. One person has been sole director and sole controller since.

Commercial signals

What to watch

• A Form D or a UK SH01, either of which would date and size any new round.
• The 2025 accounts for Digistain Limited, filed September 22, 2026, and whether the exemption is claimed again.
• Accounts for the Delaware parent, recorded as due for a period ending February 2024 and not filed.
• The multicentre clinical paper, the gate on NICE assessment and on any NHS contract.
• Whether the Madrid site converts into paid volume.

The Digistain story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Cambridge Cancer Genomics: Also in Diagnostics. A Y Combinator backed British company that used repeat blood draws and machine learning to tell an oncologist when a cancer drug had stopped working
• AminoAnalytica: Also in Diagnostics. A London founded, Imperial College spinout that began by selling AI tools to redesign industrial enzymes and peptides
• Yemaachi Biotechnology: Also in Diagnostics. An Accra company building a cancer genomic database drawn from African patients, with Roche as its anchor pharma partner
• Clear Gene: Also in Diagnostics. An RNA test built to tell a surgeon whether the whole tumor came out

Sources

1. Public recordCompanies House, DIGISTAIN LIMITED 12329264: overview, officers, control, filingsCompanies House · Sep 23, 2026
2. Public recordCompanies House, DIGISTAIN INC. FC040697 and BR025812Companies House · Sep 23, 2026
3. Public recordSEC EDGAR full text and company search for Digistain, zero filingsSEC · Sep 23, 2026
4. Public recordUKRI Gateway to Research, projects 10040802 and 10119708UKRI · Sep 23, 2026
5. Public recordClinicalTrials.gov search for the term digistain, zero studiesClinicalTrials.gov · Sep 23, 2026
6. Public recordRegister medical devices to place on the marketGOV.UK, MHRA · Sep 23, 2026
7. Public recordPatents WO2016174441A1 and GB2626541AGoogle Patents · Sep 23, 2026
8. IndependentSofia Angels Ventures helps Digistain raise $1MMedical Buyer · Aug 8, 2022
9. IndependentDigistain raised $1 million seed from Sofia Angels Ventures and Y CombinatorNordic9 · Aug 9, 2022
10. IndependentRapid breast cancer screening technology could stop unnecessary chemotherapyImperial · Oct 17, 2022
11. CompanyDigistain gets Y Combinator funding; funded by Sofia Angels VenturesDigistain · 2021 and 2022
12. CompanyDigistain company profileY Combinator · Sep 23, 2026
13. PartnerSABCS 2024 abstract P1-11-27 and the Digistain for MDs pageProtean BioDiagnostics · Jun 13, 2025

Compiled from Companies House, SEC, UKRI, MHRA and other public records and published reports as of September 22, 2026. No Form D or other Regulation D notice exists for Digistain; reported round figures come from trade press and company posts. Healthcare Venture Capital Fund holds no position in Digistain. This page is not an offer to sell or a recommendation to buy any security.